Tango Therapeutics is planning a Phase 3 pancreatic cancer study after early clinical results with vopimetostat (Tango) plus Revolution Medicines’ daraxonrasib. The report follows earlier “smashing” combination readouts discussed in the context of patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC), where Tango’s addition produced durable responses. In the same combination setting, Revolution’s RAS(ON) inhibitors have been positioned as part of an approach to extend activity in a difficult-to-treat disease, with the pairing generating response and durability signals that drove investor interest. Tango’s next step is to align the clinical program design toward registrational intent, with Phase 3 timing dependent on continued performance in ongoing cohorts and additional operational planning. The planned move highlights how quickly combination data can translate into larger, potentially pivotal trials when the efficacy signal appears strong in early-stage testing.